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Abstract
Introduction. Occupancy-over-time was determined for two dopamine transporter (DAT) inhibitors through modeling of their
ability to displace the PET ligand [
11C]CIT. The tracer was held at a pseudo steady state in a reference tissue by target
controlled infusion.
Methods. Rhesus monkeys (n = 5) were given [
11C]CIT and studied with a PET scanner. Tracer uptake in the reference tissue
cerebellum was held at a pseudo steady state by use of target controlled infusion. The pharmacokinetics/pharmacodynamics
(PK/PD) of [
11C]CIT was assessed through the simpliﬁed reference tissue model (SRTM). Bupropion (n = 2) and
GBR-12909 (n = 2) receptor occupancies were estimated through modeling of their effects on [
11C]CIT displacement.
Results. There was a high uptake of [
11C]CIT in striatum, which contains a high DAT density. The reference tissue cerebellum
had a comparatively low uptake. The modeling of [
11C]CIT PK/PD properties in striatum showed high binding potential
(BP = 5.34 ± 0.78). Both DAT inhibitors caused immediate displacement of [
11C]CIT after administration. The occupancy-
over-time was modeled as a mono-exponential function, describing initial maximal occupancy (Occ0) and rate of ligand–
receptor dissociation (koff). GBR-12909 showed irreversible binding (koff = 0) after an initial occupancy of 76.1%. Bupropion
had a higher initial occupancy (84.5%) followed by a release half-life of 33 minutes (koff = 0.021).
Conclusions. The proposed model can be used for assessment of in-vivo occupancy-over-time of DAT ligands by use of target
controlled infusion of [
11C]CIT. The concept of assessing drug–receptor interactions by studying perturbations of a PET
tracer from a pseudo steady state can be transferred to other CNS systems.
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Introduction
Positron emission tomography (PET) is a non-invasive
imaging modality where a tracer containing a positron-
emitting nuclide (such as
11Co r
18F) can be studied
in vivo over time. This study describes how a novel
system for target controlled infusion (TCI), UIPump,
canbeusedfortracermodelingandassessmentofacute
dynamicsofunlabeledpharmaceuticals.Thebasicpro-
gramming of UIPump has been described earlier (1) as
well as some of the possible applications (2,3).
[
11C]CITisatracerforstudiesofaspectsofthecentral
nervoussystem(CNS),whichbindswithhighspeciﬁcity
to the dopamine transporter (DAT), with low non-
speciﬁc binding to other structures (4). The tracer is
therefore suitable for studies of the interaction between
DAT and pharmaceutical compounds that affect the
CNS. DAT is expressed in high densities in stria-
tum, while some other structures in the brain are
almost devoid (such as cerebellum). In this study the
pharmacokinetic and pharmacodynamic (PK/PD)
properties of [
11C]CIT in striatum (both putamen and
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reference tissue modeling.
DAT exerts its effect through re-uptake of the
neurotransmitter dopamine from the synaptic cleft,
thereby regulating the postsynaptic response (5).
Changes in DAT densities have been associated to
attention deﬁcient hyperactivity disorder (ADHD) (6)
and several neurodegenerative disorders, such as
schizophrenia (7). It is also a target molecule for
DAT agonists and antagonists. These classes include
both therapeutical drugs and psychoactive drugs (such
as cocaine and amphetamine) (8). DAT antagonists
impair the re-uptake of dopamine, leading to a mod-
ulation of the pre- and postsynaptic function both
short- and long-term. These synaptic changes can
lead to withdrawal symptoms or abuse problems after
long exposure to some DAT ligands.
This study compares acute ligand–target interac-
tions immediately after administration by modeling
the occupancy-over-time based on the ability of the
compound to displace [
11C]CIT from DAT. To
study the immediate displacement of [
11C]CIT the
pharmaceuticals are administered during a PETscan,
where tracer levels are kept at a pseudo steady state in
a reference tissue (cerebellum) by using TCI. Apart
from designed infusion schemes using TCI, pseudo
steady state levels of plasma or tissue can also be
achieved by a bolus injection followed by constant
infusion of tracer, but the time until steady state is
usually longer (9–11).
Occupancy of a ligand to a target is usually deter-
mined at equilibrium. The immediate ligand–target
pharmacodynamics can be difﬁcult to quantify due to
low resolution in the assay. The PK/PD and occu-
pancy of a pharmaceutical can be evaluated based on
displacement of a PET tracer. However, in this kind
of study the patient is often pretreated (before the
scan) with the compound to allow it to reach equi-
librium in the target tissue. The initial interactions are
therefore often not included.
Different DAT-targeted pharmaceutical compounds
have different pharmacodynamics and exert short- or
long-term effects. The initial occupancy (during the
ﬁrst seconds, minutes, or hours) may or may not affect
the subject. One could for example hypothesize that a
very rapid onset of high occupancy, combined with
high retention, may trigger up-regulation of DAT
density and thereby a risk of habituation to the com-
pound. Conversely, a low initial occupancy with rapid
clearance from DAT-rich regions yields a lower risk of
causing habituation. Therefore, the onset binding and
clearance of two compounds to DAT were investigated
in this regard.
Bupropion was chosen as a model of a pharmaceu-
tical with low risk of inducing habituation, while
GBR-12909was used as amodelforacompound with
high risk of inducing habituation (such as cocaine).
Bupropion is an inhibitor of DAT, which has been
usedinthetreatmentofADHDandsmokingcessation
(12). GBR-12909 has high speciﬁc antagonistic bind-
ing to DAT with long duration and has been investi-
gated as a treatment drug for cocaine addiction (13).
Materials and methods
Animals
Five female rhesus monkeys (weight 5.4–9.7 kg; age
15–20years)were used.The animalsweresedatedwith
ketamine (7 mg/kg) before transportation to the PET
camera. One venous catheter was applied for tracer
administration and one for administration of pharma-
cological compounds and blood sampling. Propofol
was administered intravenously until the animal was
anesthetized enough for intubation. After intubation
the animal was maintained on sevoﬂurane (3%–8%)
mixed with medical air and artiﬁcial ventilation.
Blood samples were taken for estimates of electro-
lytes, glucose, and hematocrit.Blood losses were com-
pensated for with injections of albumin (50 mg/mL).
Ringer-acetate (0.5 mL/kg/h) was infused during the
whole experiment. Body temperature, heart rate,
ECG, pCO2,p O 2, SaO2, and blood pressure were
monitored throughout the PET study.
Experiments were approved by the local Ethics
Committee for Animal Research and performed in
accordance with local institutional and Swedish
national rules and regulations.
Radiochemistry
[
11C]CIT was synthesized as described previously (4).
The radiochemical purity of each batch was greater
than 95%.
Infusion system
The TCI system UIPump consists of a personal
computer and an infusion pump. For this study
a programmable Univentor 864 Infusion Pump
(AgnThos, Lidingo, Sweden) was used. The
UIPump program compares the target concentra-
tion curve with a model of the compound kinetics
after a fast bolus injection and calculates the infusion
scheme necessary for compensating the wash-out of
the compound to generate a steady state of the
compound in a speciﬁc tissue. In this study the
TCI system was used to generate a steady state in
the reference tissue cerebellum.
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The PET imaging studies were performed using
a SHR 7700 camera (Hamamatsu Photonics,
Hamamatsu, Japan). The scanner has a 14.3 
11.4 cm ﬁeld of view, and the scanner is capable of
an axial and trans-axial resolution of 2 mm. All scans
were performed in 2D. An 18.5 MBq
68Ge rotating
point source was used to acquire normalization and
blank scans. The attenuation scans were performed in
coincidence mode for 20 minutes. Dead time correc-
tion, random correction, and scatter correction were
performed for all scans. Images were reconstructed by
using 2D ﬁlter back projection.
All scans were performed with infusion of the
radiotracer calculated by UIPump, aiming for steady
state in cerebellum. The base-line scan was performed
over 100 minutes (ﬁve animals). The second scan was
performed over 110 minutes where a DAT ligand,
bupropion (n = 2) or GBR-12909 (n = 2), was admin-
istered after 60 minutes at a pharmacological dose.
All images were analyzed in IDA (Scanditronix AB,
Uppsala, Sweden). Regions of interest (ROIs) were
drawn over striatum and cerebellum in several trans-
versal slices in each subject. Each collection of ROIs
was combined into a volume of interest (VOI), and
time–activity curves (TACs) were generated from
each VOI. Standardized Uptake Values (SUV) values
were calculated by using only the amount of radio-
activity administrated by the initial short bolus. This
procedure resulted in apparently high SUV values, as
the initial bolus contributed on average only 23% of
the total administered tracer volume/activity (the
remaining 77% consisting of discrete subsequent
infusions).
Modeling of [
11C]CIT uptake
The [
11C]CIT uptake in striatum was investigated
by implementing the TCI system to achieve a pseudo
steady state in the reference tissue cerebellum. PK/PD
parameters R1,k 2, binding potential (BP), and distri-
bution volume ratio (DVR) were determined by ﬁtting
the striatal TACs to the simpliﬁed reference tissue
model (SRTM) described by Lammertsma et al.
(14). Cerebellum was used as reference region due
to its low expression of DAT. The DVR in the refer-
ence region was set to 1, assuming BPcerebellum = 0. The
model was implemented by the MatLabprogram Rz
(in-house, Uppsala Imanet AB, Uppsala, Sweden).
Assessment of occupancy-over-time
The DAT inhibitors bupropionhydrochloride (Sigma-
Aldrich, St Louis, MO, USA) or GBR-12909 (RBI,
Natick,MA,USA)weredissolvedin5mL0.1MNaCl.
They were then administered intravenously as a bolus
(5 mg/kg) 60 minutes after administration of
radiotracer.
SRTM is based on the full reference tissue model
(15). In the full model the target tissue is described
as two compartments, Cfree and Cbound. Several rate
constants(k2,k 3,andk4)determinethetracerexchange
between the compartments. The rate constantk2 deter-
mines wash-out from the tissue, while k3 and k4 rep-
resent tracer–target binding and release, respectively.
In SRTM, the ratio k3/k4 is denoted as BP and the two
compartments combined into one. The distribution
volume ratio (DVR = BP + 1) can be considered to
specify the ratio between bound and free tracer.
When a DAT inhibitor displaces [
11C]CIT in the
striatum, the tracer concentration in the region will
decrease due to active transport through the cellular
membrane. Only free tracer is available for wash-
out through k2. Therefore, an increase in wash-
out must be due to an increase in free tracer (or a
decrease in BP which determines DVR). Decrease in
BP is here assumed to equal a decrease in available
receptors for the tracer (the apparent k3becomes lower)
due to pharmaceutical binding to DAT. The occu-
pancy of all available DAT (in %) can then be calcu-
lated from the apparent decrease in BP (BPapparent)
(equation 1) due to [
11C]CIT displacement and
wash-out.
Occupancy
BP BP
BP
BP k
apparent =
−∗
=
()
,
100
3         where apparent a apparent /( ) k4 1 Eq
The change in tracer concentration in the striatum
can be described by a one-tissue compartment (equa-
tion 2). The term a is equal to the plasma concentra-
tion of tracer (Cp) multiplied by the unknown rate
constant K1.C p is assumed to be proportional to
Ccerebellum and therefore constant during the displace-
ment phase; a is subsequently treated as a constant.
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OccupancyofeachinhibitortoDATwasdescribedas
a mono-exponential function (equation 3). The con-
stantsOcc0andkoffdenoteinitialoccupancy(in%)and
ligand–target dissociation (in min
-1), respectively.
There is always an ‘absorption phase’ (usually very
short) before the maximal initial occupancy is reached.
Theabsorptioncanbedescribedbyanadditionalexpo-
nential term in the function, but it is not included here
for simplicity.
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Equations 1–3 were combined into equation 4,
which was ﬁtted discretely to the experimental data
for each DAT inhibitor in MatLab. Best ﬁtw a s
determined iteratively through residual sum of
squares.
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Results
Bolus curve acquisition
The UIPump bolus input curve was modeled
after TACcurves over cerebellum from earlier
experiments (n = 6) where [
11C]CIT was
administered intravenously (data not shown). The
curve in Figure 1 is the mono-exponential curve
(t1/2 = 13.2 min; plateau at 16.2% of initial value)
with best ﬁt to the individual bolus responses in
previous experiments.
Base-line acquisition
The bolus input curve was used to program an infu-
sion scheme to reach a pseudo steady state of [
11C]
CIT in the cerebellum. Uptake in striatum
(Figure 2A) increased close to linearly during the
entire scan under these conditions, indicating that
the interaction between tracer and target was almost
irreversible (Figure 2B).
Modeling of [
11C]CIT uptake
Results from ﬁtting SRTM to striatum using cerebel-
lum as a reference region are presented in Table I.
Each subject was modeled individually. Parameters are
given as averages ± SEM. The estimated k2 rate con-
stant values (mean k2 = 0.10 ± 0.1) conﬁrmed that
[
11C]CIT has close toirreversible binding properties in
striatum.BPwashighin allsubjects (meanBP= 5.34 ±
0.78); especially subject 3 (BP = 8.14) which is the
source of the majority of variation in SEM.
Assessment of occupancy-over-time
Both bupropion and GBR-12909 immediately dis-
placed [
11C]CIT in striatum (Figure 3). There was no
decrease in the cerebellum, conﬁrming that the
uptake of [
11C]CIT in the reference tissue was
non-displaceable (uptake consists entirely of free or
non-speciﬁc binding).
Bupropion and GBR-12909 occupancy could be
modeled according to equation 4 above (Table II).
GBR-12909 showed lower initial occupancy than
bupropion(76.1% compared to 84.5%). The retention
of GBR-12909 was very high, however, with a
koff = 0 as best ﬁt.This indicates completelyirreversible
binding to DAT, at least within the ﬁrst hour investi-
gated here. If this assessment is true or a limitation of
the model will be discussed below. Bupropion–DAT
dissociation was determined as koff = 0.021, or as
having a retention half-life of 33.0 minutes.
Discussion
This study aimed to show that the technique of
holding a PET tracer at a pseudo steady state in a
reference tissue by TCI can be used to determine
early changes in receptor occupancy of unlabeled
pharmaceuticals at their site of action, as well as
quantifying the rate of offset (koff).
The PK/PD of the radiotracer [
11C]CIT was
assessed by a simpliﬁed reference tissue model. The
level of the tracer in the cerebellum was held constant
through target controlled infusion by UIPump (using
a cerebellum input function modeled from several
previous experiments). Preferably, the target tissue
should be held at steady state, but this was not
possible in this speciﬁc case since there is virtually
no clearance of [
11C]CIT from the striatum due to its
very strong binding to DAT. The high BP in striatum
(5.34 ± 0.78) obtained from the model is consistent
with this reasoning.
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Figure 1. The response of [
11C]CIT in cerebellum was modeled
from TACs from six previous experiments where the tracer was
administered as an intravenous bolus. Error bars indicate standard
deviation. The model curve was used to calculate the infusion
scheme required to achieve pseudo steady state of tracer in
cerebellum.
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compoundandatargetinvivo(forexampleinananimal
model or in patients) with PET, the PK/PD of the
compound is essentially determined indirectly through
thedisplacementoftheadministeredPETtracer.Often,
the unlabeled compound is administered some time
before the tracer to reach equilibrium. In that case,
the initial kinetics and dynamics have already occurred
at the time of tracer administration and PET scanning.
This study showed that all phases of the PK/PD of a
compound (including the initial kinetics) can be inves-
tigated indirectly throughperturbationsof a PET tracer
at pseudo steady state in a reference tissue.
The perturbations of the radiotracer steady state
due to an unlabeled compound were quantiﬁed as
changes due to ligand–target occupancy-over-time.
The occupancy model omitted the absorption phase
entirely and focused solely on the clearance phase. To
study the absorption phase, which can be very rapid,
the model probably would need to have resolution
and robustness enough to determine large changes
during the ﬁrst minute(s).
Previous PET studies in humans have determined
bupropion occupancy of DAT to 26% (steady state
dose regimen, 150 mg dose 3 hours prior to scan (16))
and 14% (steady state dose regimen, 150 mg dose
8–15 hours prior to scan (17)). In this study bupro-
pion was found to have a high initial occupancy
(84.5%) and a retention half-life of 33 minutes
(5 mg/kg dose in rhesus monkey). The clearance
would reduce the initial occupancy to the previously
reported values in 1–2 hours.
GBR-12909 showed high initial occupancy of
76.1% combined with zero release during the ﬁrst
60 minutes. The occupancy is consistent with a
previous PET study in rhesus monkey, where doses
of 3 and 10 mg/kg bupropion 90 minutes later
produced DAT occupancies of 53% and 72%,
respectively (18). The very low release seen here
indicates a long-term occupancy, which has been
previously seen in both rats and rhesus monkeys
(13). The optimal model ﬁt for GBR-12909-induced
displacement was not ideal. This may be due to the
fact that the absorbance phase was omitted from the
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Figure 2. Target-controlled infusion to reach pseudosteady state of [
11C]CITin cerebellum. As expected, there was high uptake localized to
striatum, as shown in a trans-axial projection of a representative subject (A). The pseudosteady state of [
11C]CITin cerebellum resulted in
elevated, close to irreversible striatal uptake (B). Error bars indicate SEM (n = 5).
Table I. Kinetic parameters for [
11C]CIT PK/PD in striatum determined from the simpliﬁed reference tissue model. The majority of variation
in BP and DVR is due to the elevated values in subject 3.
Parameter Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Average SEM
R1 0.58 1.09 1.47 1.17 0.84 1.03 0.15
k2 0.13 0.08 0.12 0.07 0.07 0.10 0.01
BP 3.85 4.18 8.14 4.69 5.87 5.34 0.78
DVR 4.85 5.18 9.14 5.69 6.87 6.34 0.78
DVR ref 1 1 1 1 1 1 -
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koff.Ak off b e l o wz e r oi so fc o u r s ei m p o s s i b l ei na
biological system, but it indicates that occupancy
rose slightly during the ﬁrst hour after initial
displacement.
The model for habituation hypothesized in the intro-
duction was based on the initial occupancy (Occ0)a n d
the concentration- and time-dependent release (koff).
For these two compounds Occ0 differed very little.
Bupropion, which has a steady state dose regimen at
low occupancies, was found to have a higher Occ0 than
GBR-12909. Both compounds exert noticeable initial
binding to DAT.
In contrast koff differed greatly between the com-
pounds where bupropion was released with a short
half-life (only 25% of the binding remains after
approximately 1 hour). GBR-12909 essentially binds
irreversibly which could lead to a prolonged DAT
inhibition resulting in more prominent downstream
regulation to the striatal dopamine system than that
seen after bupropion administration.
In conclusion, the proposed model can be used for
assessment of in vivo occupancy-over-time of DAT
ligands by use of target controlled infusion of [
11C]
CIT. The concept of assessing drug-receptor interac-
tions by studying perturbations of a PET tracer from a
pseudo steady state can be transferred to other CNS
systems.
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